-- Robin Washington, Paul Carter and John McHutchison, MD Named
Executive Vice Presidents --
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 27, 2014--
Gilead Sciences, Inc. (Nasdaq: GILD) today announced several promotions
within the company’s senior management team. Robin Washington, Chief
Financial Officer (CFO), has been promoted to Executive Vice President;
Paul Carter, formerly Senior Vice President, International Commercial
Operations, has been promoted to Executive Vice President with
responsibility for Gilead’s worldwide commercial organization; and John
McHutchison, MD, formerly Senior Vice President, Liver Disease
Therapeutics, has been promoted to Executive Vice President and will
assume additional responsibility for clinical development programs in
the areas of oncology, respiratory diseases and inflammation.
“Robin, Paul and John have made significant contributions to Gilead,
each demonstrating a commitment to improving systems and processes and
advancing programs that will allow us to meet the needs of patients as
quickly as possible,” commented John C. Martin, PhD, Chairman and Chief
Executive Officer, Gilead Sciences. “They have each built strong,
capable teams and have helped Gilead navigate an increasingly complex
environment as we expand geographically and into new therapeutic
categories. Their leadership and vision will help ensure Gilead is able
to achieve our goals and reach more patients in need around the world.”
Ms. Washington joined Gilead in 2008 as Senior Vice President and CFO.
She oversees the company’s finance, information technology and investor
relations functions, reporting to John Milligan, PhD, Gilead’s President
and Chief Operating Officer. Prior to joining Gilead, Ms. Washington was
Chief Financial Officer of Hyperion Solutions, which was acquired by
Oracle Corporation in March 2007. She previously served in a number of
executive positions with PeopleSoft, most recently in the role of Senior
Vice President and Corporate Controller. Ms. Washington is a member of
the Board of Directors of Honeywell International, the Board of
Directors of Salesforce.com and the Board of Visitors, Graziadio School
of Business and Management, Pepperdine University. She is a certified
public accountant and holds a bachelor's degree in business
administration from the University of Michigan and an MBA from
Pepperdine University.
Mr. Carter joined Gilead Sciences in April 2006 to head its European
commercial organization. Later that year he assumed additional
responsibility for Gilead’s growing operations outside of Europe and
North America. He has helped to establish the company’s regional Asian
headquarters in Hong Kong and numerous new affiliate offices, most
recently including operations in the Czech Republic, Poland, Russia and
South Korea. In his new role, Mr. Carter will oversee worldwide
commercial operations, reporting to Dr. Milligan. Prior to joining
Gilead, Mr. Carter spent 15 years in the pharmaceutical industry with
GlaxoSmithKline and its legacy companies. During his time with GSK, Mr.
Carter gained increasing levels of senior experience as General Manager
in Europe and later as a Regional Head of the International business in
Asia. In this latter role he was also a member of GSK’s International
Management Committee. Mr. Carter’s early experience includes several
years with Arthur Andersen at its London office. He has a degree in
Business Studies from the Ealing School of Business and Management (now
merged into University of West London) and is a Fellow of the United
Kingdom’s Chartered Institute of Management Accountants.
Dr. McHutchison joined Gilead in 2010 as Senior Vice President, Liver
Disease Therapeutics. In his newly expanded role, he will be responsible
for Gilead’s development programs in oncology, respiratory diseases and
inflammation. Dr. McHutchison will continue to report to Norbert
Bischofberger, PhD, Executive Vice President, Research and Development
and Chief Scientific Officer. Prior to joining Gilead, Dr. McHutchison
worked at Duke University Medical Center, where he served as Associate
Director of the Duke Clinical Research Institute. He also held the
positions of Professor of Medicine in the Division of Gastroenterology
at Duke University Medical Center and Co-Director of the Duke Clinical
and Translational Science Award. Prior to his positions at Duke, Dr.
McHutchison spent nearly 10 years at Scripps Clinic, most recently as
Medical Director, Liver Transplantation. He also previously held an
Assistant Professorship in Medicine at the University of Southern
California. Dr. McHutchison received bachelor of medicine and bachelor
of surgery degrees from the University of Melbourne, Australia, and
completed his residency in internal medicine and a fellowship in
gastroenterology at the Royal Melbourne Hospital. He is also a member of
the Royal Australasian College of Physicians.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases worldwide. Headquartered in Foster City,
California, Gilead has operations in North and South America, Europe and
Asia Pacific.
Forward-Looking Statement
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks, uncertainties and other factors. These risks,
uncertainties and other factors could cause actual results to differ
materially from those referred to in the forward-looking statements. The
reader is cautioned not to rely on these forward-looking statements.
These and other risks are described in detail in Gilead’s Quarterly
Report on Form 10-Q for the quarter ended September 30, 2013, as filed
with the U.S. Securities and Exchange Commission. All forward-looking
statements are based on information currently available to Gilead, and
Gilead assumes no obligation to update any such forward-looking
statements.
For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com,
follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at1-800-GILEAD-5 or 1-650-574-3000.
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.Patrick O’Brien, 650-522-1936 (Investors)Amy
Flood, 650-522-5643 (Media)
